4.6 Article

Growth Differentiation Factor 15 Is a Cancer Cell-Induced Mitokine That Primes Thyroid Cancer Cells for Invasiveness

Journal

THYROID
Volume 31, Issue 5, Pages 772-786

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/thy.2020.0034

Keywords

mitochondrial stress; mitochondrial unfolded protein response; GDF15; STAT3; cancer; thyroid cancer

Funding

  1. National Research Foundation of Korea (NRF) - Ministry of Science, ICT, and Future Planning [NRF-2017R1D1A1B0 3027820, NRF-2019R1H1A2079938, NRF-2019R1A2C10 84125, NRF-2017R1A5A2015385]
  2. Global Research Laboratory (GRL) Program through the National Research Foundation of Korea (NRF) - Ministry of Science and ICT [NRF-2017K1A1A2013124]
  3. Korea Science and Engineering Foundation (KOSEF) - Korea government (MOST) [2019M3E5D1A02068560]
  4. Chungnam National University Hospital Research Fund, 2015
  5. National Research Foundation of Korea [2019M3E5D1A02068560] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

The study revealed that mitochondrial stress induces the expression of GDF15 in thyroid cancer cells, and GDF15 promotes tumor invasion by activating STAT3. Therefore, the GDF15-STAT3 signaling axis may serve as a potential therapeutic target for thyroid cancer aggressiveness.
Background: Mitochondrial stress is known to activate the mitochondrial unfolded protein response (UPRmt). The UPRmt results in the secretion of mitochondrial cytokines (mitokines), which can promote a hormetic response cell nonautonomously, and has been reported to be protumorigenic. Growth differentiation factor 15 (GDF15) is a well-characterized mitokine, which is reported to have a mitohormetic effect. Thus, we investigated whether GDF15 induction could prime a subpopulation of thyroid cancer cells to provide invasive advantages. Methods: The UPRmt, including mitokine expression, was assessed in the context of thyroid cancer in vitro and in vivo. GDF15 expression in 266 patients with papillary thyroid carcinoma (PTC) was determined by immunohistochemistry. The serum levels of GDF15 were measured in healthy subjects and PTC patients. In addition, our own and The Cancer Genome Atlas data were analyzed to determine the expression level of GDF15 in thyroid cancers. The role of GDF15 in tumor aggressiveness was investigated by observing the effects of GDF15 knockdown in BCPAP, TPC-1, 8505C, and FRO cells. Results: Pharmacological inhibition of mitochondrial oxidative phosphorylation function in thyroid cancer cells robustly increased GDF15 expression. The expression of GDF15 was associated with activation of the mitochondrial integrated stress response pathway in PTC patients. Circulating GDF15 levels were significantly higher in PTC patients than in the controls, and tumor expression of GDF15 was related to tumor aggressiveness. In vitro and in vivo knockdown of GDF15 in a thyroid cancer model showed decreased viability, migration, and invasion compared with the control cells via regulation of STAT3. Conclusions: In this study, we demonstrated that GDF15 is a mitokine induced in thyroid cancer cells upon mitochondrial stress. GDF15-induced STAT3 activation determined tumor progression in thyroid cancer. The GDF15-STAT3 signaling axis may be a target in aggressiveness of thyroid cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available